Prof. S. Dhar I came across an article in Science Illustrat ed about "The top 10 challenges for the coming decade" in human health (Science Illustrated 2011, page 54, Jan/Feb issue). This list included mapping the metabolic system, aging, targeted cancer therapy, obesity, malaria, etc. When I start ed my independent research program, this article made me think what a chemist with keen interest in solving biomedical problems can do. I looked for common connecting points for these problems to apply my expertise in chemistry, biology, and nanotechnology. I realized if I can focus at the basic level, for example, to mitochondria, which are common connecting points in all these problems, and apply my knowledge, we might have a platform technology. Mitochondrial dysfunc tions are involved in most of these diseases. However, most available mitochondriaacting therapeutics face tremendous challenges in reaching the mitochondrial lumen where the therapeutic targets are located. A major focus of my research group is the study and development of nanocarriers for tar 
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Shanta Dhar is originally from West Bengal, India. She obtained her Bachelor of Science degree with honors in chemistry from the University of North Bengal and she was a silver medalist. She then received her Masters in Science with inorganic chemistry specialization and she was a gold medalist. She pursued her PhD at one of India's finest institutions of higher edu cation -the Indian Institute of Science, Bangalore -under the supervision of Professor Akhil R. Chakravarty. Her thesis work in the area of Metals in Medicine received a "Best Thesis" award for chemical sciences. 
SYNFORM When did you get interested in synthesis?
Prof. S. Dhar My love for organic synthesis started in col lege. I remember even trying to teach my little brother, 10 years younger than me, some organic synthesis during my college days when he was in elementary school. During my college days, one of my teachers would challenge me with organic mechanisms and organic transformations. I special ized in inorganic chemistry during my masters training and conduct ed my PhD in bioinorganic chemistry, and I always enjoyed organic and inorganic synthesis. In my PhD, I was synthesiz ing copper(II) ternary complexes, which were inter preted as difficult to synthesize. I ended up synthesizing nu merous ternary complexes and was even able to get 18 such complexes characterized by singlemolecule Xray crystallo graphy. I love doing synthesis. I then had a oneyear bootcamp organic synthesis training in Professor Greenberg's lab and I really got interest ed in doing organic synthesis and the new molecules one can construct using organic reactions. This training helped me to integrate organic and inorganic synthe tic strategies together to create small and macromolecules. At MIT, I fell in love with synthetic aspects dealing with platinum complexes by taking advantage of different oxidation states and geometries that this precious metal offers.
SYNFORM What do you think about the modern role and prospects of organic synthesis?
Prof. S. Dhar Being a chemist who aims to use synthetic chemistry to develop organic and inorganic molecules, nano delivery vehicles, and combination therapeutic approaches for medical/biological applications, I would like to express my view of the role and prospects of organic synthesis by quoting the exciting comment of German chemist Friedrich Wöhler after he synthesized urea and wrote to his mentor "...I cannot, so to say, hold my chemical water, and must tell you that I can make urea, without thereby needing to have kidneys, or any how, an animal, be it human or dog..." Organic synthesis pro vides a valuable tool towards recreating biologically relevant compounds for a multitude of different purposes. In addi tion to traditional medicinal chemistry, organic synthesis has the power to truly transform the field of nanomedicine and bioinorganic chemistry. One of the major challenges we often observe in nanomedicine is to reproducibly construct drug loaded materials when we consider advancing these unique technologies to the clinic. Organic synthesis has the potential to provide solutions to these problems; one can use unique organic synthetic strategies to reproducibly make these ma terials. Platinum complexes with antitumor properties are the most conspicuous representatives in medicinal inorganic chemistry and organic synthesis provided tools to modify the completely inorganic parent compound cisplatin, resulting in the platin-based subfield of bioinorganic chemistry. The im pact of organic synthesis in medicine in the last two centuries has been extraordinary and this will continue to happen as organ ic synthetic chemists find sophisticated synthetic strate gies. Organic synthesis will continue to influence the growth of nanomedicine, metalbased medicine, and other relevant fields in medicine. Prof. S. Dhar Mitochondria are not only the energy facto ries of cells but these dynamic organelles participate in the overall process of cellular mortality; thus, their dysfunctions lead to various diseases such as cancer, atherosclerosis, and neurodegenerative diseases in addition to conventional mito chondrial dysfunctionrelated diseases. To tackle these di seases, one needs to access the targets, which are located in mitochondrial lumen. Targeting mitochondria has been notor iously challenging due to their complex and dynamic na ture. My lab is actively involved in generating biodegradable, tunable nanodelivery vehicles for efficacious mitochond rial delivery of therapeutics for cancer, neurodegenerative diseases, and cardiovascular diseases. As we move forward, we plan to expand the application of such nanoparticle (NP) based platforms to other diseases where mitochondria and their abnormalities play integral roles. We also discovered that suitably optimized mitochondriatargeted NPs could dis tribute in the brain and we are working on the potential of mitochondriatargeted lipophilic biodegradable NPs with the ability of traversing the blood-brain barrier in neurodegene rative diseases and brain cancers.
SYNFORM
Coronary events continue to be the leading cause of death in the United States. We are active in applying our synthetic chemistry to construct synthetic, biodegradable, mitochond riatargeted NP platforms with the ability to participate in extra and intracellular lipid reduction pathways for cardio vascular diseases.
We have several programs developing alternative thera peutic platforms for cancer. One of the effective methods to tackle metastatic cancers will be to engage our immune sys tem. We use a unique combination of mitochondrial stimu lation of cancer cells using targeted NPs and light to activate the immune system. Targeting mitochondrial DNA (mtDNA) can be important for cisplatinbased chemotherapy. Cisplatin is a widely used and FDAapproved chemotherapeutic agent which is highly effective against several cancers. Therapeu tic action of cisplatin relies on its ability to form interstrand and intrastrand nuclear DNA (nDNA) crosslinks. Resistance to cisplatin-based chemotherapy arises from different cellular processes, one of which is accelerated DNA repair by nucleo tide excision repair machinery. The absence of such repair machinery in the mitochondria and enhanced mtDNA mu tation in aggressive cancers motivated us to reroute cisplatin to attack mtDNA. We are developing such technologies for nanoparticlemediated cisplatin delivery in the form of activ able prodrugs to the mitochondria of different cancer cells to attack mitochondrial genome for chemoresistant cancers.
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In the search for a successful treatment, it is evident that a single magic bullet is not enough for metastatic cancers. How ever, systemic administering of bolus doses of multiple thera peutics often results in intense side effects. We are engineering polymers with biodegradable dendrons at the termini through direct conjugation to incorporate anti-inflammatory drugs, chemotherapeutics along with cancer cell target ing moieties to provide an allinone therapeutic NP platform for metastatic cancers.
Cancerrelated mitochondrial alterations such as defective oxidative phosphorylation, mitochondrial biogenesis, down regulation of ATP synthase, and mitochondrialreactive oxy gen species provide unique targets for selective treatment mo dalities. Thus, engineering of small molecules known to work at different targets inside the mitochondria or developments of such molecular payloads containing mitochondriatargeted NPs have the potential to provide tumor-specific anticancer agents. We are involved in the development of mitochondria targeted prodrugs that can be locally activated at the target sites: some examples are dichloroacetic acid, 3bromopyru vate, Bcl2 inhibitors.
SYNFORM What is your most important scientific achievement to date and why?
Prof. S. Dhar My most significant research accomplish ment to date is the development of a biodegradable nanopar ticle platform from Food and Drug Administration approved components for mitochondrial dysfunctionrelated diseases. This technology can be useful to study a wide range of human diseases where mitochondrial dysfunction is a major player. This platform technology has resulted in several other import ant contributions, including the first synthetic mitochondriatargeted nanoparticle that can mimic the functional behaviors of highdensity lipoprotein for potential applications in coron ary artery disease, the ability to generate functional immune cells in vitro for cancer vaccines, providing an alterna tive tar get to platinumbased drugs for overcoming resistance, the development of biodegradable dendronfunctionalized poly meric nanoparticles for combination therapy, mitochondria targeted metabolic reprogramming of cancer cells, and the evaluation of nanoparticlebased neuroprotection therapy for brain injury.
A165

Literature Coverage Synform A166
The field of photoredox catalysis has grown exponentially in the last decade because it provides synthetic chemists with a means to perform free-radical reactions under mild conditions and irradiation from simple, household light sources. In a vast majority of the contributions, these transformations have been mediated by transition-metal catalysts, in particular polypyridyl ruthenium and iridium complexes, decreasing the economic benefit of these reactions. However, the possibility of using metal-free catalysts, such as organic dyes, for achieving efficient light-mediated photoredox reactions is an attractive option, as they offer a variety of environmental and economic benefits. Recently, the group of Professor Juan C. (Tito) Scaiano from the University of Ottawa (Canada) has reported a systematic study of the efficiency of cationic organic dyes as catalysts for photoredox transformations. In this work, the ability of four different classes of organic dyes to mediate photoredox transformations was examined using two model reactions, the debromination of meso-1,2-dibromo-1,2-diphenylethane, and the nitromethylation of a tertiary amine at the α-amino position, also known as the light-mediated aza-Henry reaction (Scheme 1). The authors were able to correlate the observed activity of the organic dye with the rate constants of mechanistically key steps, demonstrating the importance of proper kinetic analysis for understanding the underlying mechanism of photoredox systems. However, the goal of this contribution by Scaiano and co-workers was not only to demonstrate that these dyes can mediate photoredox reactions, but also to increase their popularity among practitioners of photoredox by carefully analyzing all of the relevant photophysical and electrochemical properties of these dyes, and to compile this information in a single, open-access contribution that would allow practitioners of photoredox easy access to the data.
"The popularity of transition-metal catalysts, in particular Ru(bpy) 3 Cl 2 , in photoredox transformations stems from the fact that these complexes are well characterized in the literature. In fact, much of this data has been available since the 1970s for many of these complexes, including countless reviews on the photophysics of Ru(bpy) 3 Cl 2 ," said Professor Scaiano. "On the other hand, organic dyes, which we have shown can be excellent metal-free alternatives for photoredox transformations, do not have the same collection of data available. Therefore, chemists who practice photoredox catalysis tend to stick with catalysts where the electrochemistry and photophysics are already known, instead of using organic dyes where the same data is either unknown or difficult to find," he added.
Professor Scaiano explained: "We hand-picked 13 different organic dyes, as well as three popular photoredox catalysts in Ru(bpy) 3 Cl 2 , Ir(ppy) 3 , and 9-mesityl-10-methylacridinium Literature Coverage Synform perchlorate, and fully characterized both their photophysical and electrochemical properties. We compiled these data, and included them as an Appendix section in our recent contribution in ACS Omega." The Appendix, located in the later pages of the manuscript, provides 'cards' with detailed descriptions of all the relevant photophysical and electrochemical data chemists who practice photoredox would require to design a photocatalytic system. An example of information the Appendix provides is demonstrated in Figure 1 , which shows the Appendix 'card' for the thiazine dye Methylene Blue.
To conclude, Professor Scaiano stated: "We envision that this collection of data will help popularize organic dyes as photoredox catalysts, as for the first time all the pertinent information for these dyes will be easily accessible in a single document." 
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3-Acyltetramic acids are metabolites of a variety of marine and terrestrial species such as sponges, bacteria, fungi, and lichens with an impressive range of biological and pharmacological activities. "This, and the scurrility that compounds with such deceptively 'simple' looking structures can turn out to be a nightmare when it comes to purification or spectral interpretation, has attracted the interest of synthetic organic chemists," said Professor Rainer Schobert from the University of Bayreuth (Germany). "Our group got involved with these compounds some twenty years ago when we serendipitously found a new Wittig-based access to their pyrrolidine-2,4-dione core. Since then we have learned the hard way that each structural subclass of 3-acyltetramic acids requires its own synthetic approach." Professor Schobert explained: "When we focus on derivatives of marine origin there are, for example, the chemically robust melophlins, metabolites of bacteria that dwell on the sponge Melophlus sarassinorum, which can be readily synthesized by an acylation of the parent pyrrolidine-2,4-dione with the respective carboxylic acid chloride in the presence of an excess of BF 3 ·OEt 2 according to a method by Raymond Jones.
1 " He continued: "In contrast, epicoccamide D, which is produced by the fungus Epicoccum purpurascens associated with the jellyfish Aurelia aurita, and which is comprised not only of polyketide and amino acid as all 3-acyltetramic acids, but also of a mannose, would not stand being steeped in Lewis acid. Its side chain had to be installed by other means prior to ring closure via a Dieckmann condensation as the final step ( Figure 1) .
2 " The genuine sponge metabolite aurantoside G posed even more intricate problems. "It is a deep-red solid which confers this color to the sponge (Figure 2 , right, shows a protected derivative of the same color) and it is moderately active against Candida albicans.
3 This antifungal activity depends on the β-linkage between tetramic acid and sugar," explained Professor Schobert, continuing: "Given that aurantoside G is a natural product it is amazingly sensitive, and so are its components. Its chlorinated, highly unsaturated side chain is sensi tive to light and prone to decomposition. Figure 2 shows a flask with its golden thioester which was built up by consecutive Wittig and HWE olefinations as planned by Sebastian Loscher and Markus Petermichl as early as in 2014." Professor Schobert recalls that Sebastian Loscher, who was then nearing the end of his PhD project, and Markus Petermichl, at that time embarking on his MSc project, also explor ed ways to attach a sugar to the nitrogen of a model 3-acyl tetramic acid, but found it was not practicable. More successful were attempts to attach a protected xylose to an Nnosylated alanine ester via a Fukuyama-Mitsunobu reaction. 
Total Synthesis of Aurantoside G, an N-β-Glycosylated
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Professor Schobert said: "In the end, it took Markus a year and a half in the lab to synthesize aurantoside G by starting out on the basis of these exploratory experiments and circumventing a host of unforeseeable problems cropping up at almost every step." Scheme 1 outlines the synthetic route that was eventually worked out. "Markus first attached the D-xylose to the asparagine by a Fukuyama -Mitsunobu reaction, which requires the nitrogen to be nosylated in order to render its hydrogen atom acidic enough," said Professor Schobert. "The actual glycosylation of this relatively electron-poor nitrogen atom was then possible only with electron-releasing p-methoxybenzyl (PMB) protecting groups on the sugar, as Markus and Sebastian had found out during their exploratory studies with alanine esters."
The resulting N-nosyl-N-xylosylasparaginate was de-nosylated to give building block 1 (red). This had to be N-acylated with the thioester 2 shown in Figure 2 . "This thioester was synthesized in 11% yield over nine steps starting from (Z)-3-chlorobut-2-en-1-ol, which was prepared by reaction of but-2-yn-1-ol with Red-Al and N-chlorosuccinimide (NCS)," said Professor Schobert, who continued: "The stepwise chain elongation of this alcohol, by employing three cycles of domino oxidation-Wittig olefination using MnO 2 and Ph 3 P=CHCO 2 Et followed by reduction of the product esters with DIBAL-H, afforded a pentenal. Due to its instability, it was immediately subjected to a HWE reaction with Steve Ley's S-tert-butyl 4-(diethylphosphono)-3-oxobutanethioate 4 to give the desired thioester 2." A169 Scheme 1 Synthetic route to aurantoside G This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
The aminolysis of thioester 2 with a mixture of anomers of methyl N-D-xylosylasparaginate 1 and silver trifluoroacetate according to Ley's general protocol 5 afforded the corresponding β-keto amide (not shown in Scheme 1) as a pure β-isomer in 49% yield with respect to recovered, unreacted 1. "Apparently, only the β-anomer of 1 enters into a reaction with 2, due to the directing effects of the PMB groups. The recovered α-anomer was re-epimerized during workup," said Professor Schobert, who revealed that it took several cycles to convert the entire 1 into the β-keto amide. Cleavage of its PMB groups with anisole gave the unprotected β-keto amide as a separable 1:1 mixture of keto (shown in Scheme 1) and enol tautomers. "Only the keto tautomer could be cyclized with NaOMe by a Dieckmann condensation to afford pure aurantoside G in quantitative yield (3.7% overall yield). The enol tautomer need ed to be re-equilibrated with acid to give the initial mixture of tautomers," said Professor Schobert, adding: "There are several lessons we have learned from this synthesis: the PMB groups were crucial for its success by enabling the FukuyamaMitsunobu reaction electronically (electron-releasing effect) and by controlling the β-selective N-acylation sterically. The Dieckmann cyclization may be used for the synthesis of even delicate tetramic acids. It does not give rise to partial racemization at the C-5 of the heterocycle, nor does it interfere with highly unsaturated fragments or unprotected sugars. So, this synthetic route should be applicable also to other, more complex N-β-glycosylated congeners of aurantoside G."
Professor Schobert concluded: "The mind-boggling sensitivity of aurantoside G -after all a natural product! -is not without precedence. Kalesse and Hartmann had a similar experience with the related lipomycins. 6 What might stabilize such compounds within the producing organism is an interest ing question to muse on."
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A recent article published by the group of Professor David Nagib from The Ohio State University (USA) describes a highly innovative chemical method that enables the δ-amination of secondary C-H bonds within a large range of unactivated amines bearing biologically relevant functionalities (Scheme 1).
Professor Nagib explained: "This work is the first discovery from our lab that we expect will serve as the cornerstone of our entire program focused on remote C-H functionalization. As we set out to begin our research on selective C-H functionalization, we quickly realized that a general strategy for the δ-amination of secondary C-H bonds remains an unsolv ed problem." In fact -as explained by Professor Nagibalthough the century-old Hofmann-Löffler-Freytag (HLF) reaction (Scheme 2) has been developed to solve this challenge in the context of biased amines containing weak C-H bonds (e.g. tertiary, benzylic, α-oxy), a solution does not yet exist for applying this approach to the δ-selective amination of secondary C-H bonds.
"It is understood that the requisite use of I 2 in the modified Suarez-HLF reaction limits synthetic scope and utility due to competitive byproducts associated with I 2 decomposition," said Professor Nagib. "Others have attempted to address this I 2 problem through portion-wise or sub-stoichiometric addition of I 2 ; however, neither approach has been able to solve the long-standing challenge for δ-amination of unbiased, secondary C-H bonds, due to the either insufficient or excessive reactivity of those methods." Professor Nagib continued: "In this manuscript, we present ed a new strategy in which I 2 is prepared in situ from NaI and rapidly trapped as a triiodide (I 3 -) species (Scheme 3). By sequestering the necessary, albeit prone to forming by-products, I 2 as I 3 -, we have demonstrated that this new triiodide strategy can solve the ongoing synthetic challenge of δ-amination of unactivated, secondary C-H bonds." "At first, we had been trying to catalyze this reaction also with CuI," explained Professor Nagib. He added: "Yet, we were amused that as we added less and less catalyst (while adding more NaI salt), we still observed the same (or better) efficiency. We ultimately decided that the only thing better than 1-2% catalyst loading is 0%. And replacing it with salt, which is nearly free, is great too!" 
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During his undergraduate studies, Ethan Wappes' research was in the field of organic electrochemistry. "The moment Ethan realized that triiodide -a common electron mediator in batteries -was the key to solving this synthetic method, it was a very fortunate déjà vu experience!" said Professor Nagib.
The broad impact, significance, and synthetic utility of this triiodide strategy have been demonstrated in the δ-amination of a wide range of amines containing unbiased, secondary C-H bonds (Scheme 4). "Notably, many of the pyrrolidine products that we efficiently generate through this approach have been previously inaccessible due to the limitations of the I 2 -based methods," said Professor Nagib. "Furthermore, the broad tolerance of this transiently trapped I 3 -approach to biologically relevant functionality (e.g. ethers, esters, ketones, arenes, and organofluorines) suggests that this strategy will have broad applicability across many research areas at the frontiers of organic synthesis."
"Importantly, this manuscript includes significant mechanistic evidence to support the role, presence, and utility of triiodide in our hypothesized strategy," remarked Professor Nagib. "For example, UV-Vis spectroscopic evidence of this reaction confirms the presence of increasing triiodide absorption that correlates with increasing (and unprecedented) reaction efficiency in the presence of added NaI. Furthermore, sequestration of I 2 as I 3 -, which we proposed would lead to efficient product formation, is corroborated by significantly cleaner crude 1 H NMR spectral data that indicate a termination of the major byproduct formation pathways (Figure 1 )."
He continued: "Perhaps most importantly, we have intercepted and characterized a pair of proposed intermediates by replacing the NaI starting material for NaCl or NaBr salts. These examples of interrupted mechanisms point to the mildness of this new reaction method as well as the opportunity to extend this strategy to avoiding unwanted byproducts in other polyhalide-mediated reactivity."
Professor Nagib revealed that in a private communication, Professor Richmond Sarpong of UC Berkeley (USA) has called this work a "Nice solution to an age-old problem!" Additionally, he has expressed interest "in using robust ways (like yours) in alkaloid synthesis" and even stating: "There is a total synthesis we are working on where this could come in handy." Professor Nagib concluded: "We anticipate that due to the prevalence of pyrrolidines in pharmaceuticals (fifth most common heterocycle in US FDA approved drugs) this chemistry 
